Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2017Journal of the American Heart AssociationOpen Access

Implantable Cardioverter‐Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications

View Full Paper
Ask AI
Bookmark
Share

Key result

Inducibility at electrophysiology study independently predicted appropriate ICD therapy in patients with ARVD/C (HR 2.28; 95% CI 1.10-4.70; P=0.025).

Population

312 patients with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy who received an…

Design

Cohort

Follow-up

8.8±7.33 years

Authors

GOGabriela M. OrgeronCJCynthia A. JamesARAnneline Te Riele

Discussion

Loading...

Member takes

Overview

May aid ARVC risk stratification via EP study and PVC burden; leaves open prospective validation before guiding decisions.

Study Design

Type

Cohort (n=312)

Structured PICO

P
Population
312 patients with definite arrhythmogenic right ventricular dysplasia/cardiomyopathy who received an ICD, followed for a mean of 8.8 years.
E
Exposure
Implantable cardioverter-defibrillator (ICD) placement
O
Outcome
Appropriate ICD therapy and intervention for ventricular fibrillation/flutterhard clinical

Main Result

Hazard Ratio: 2.28 (95% CI 1.1–4.7)

p-value: p=0.025

In patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, inducibility at EP study, younger age, and high PVC burden are independent predictors of appropriate ICD therapy and potentially fatal ventricular arrhythmias, aiding in risk stratification.

Cite This Study

Orgeron et al. (2017) conducted a cohort in Arrhythmogenic right ventricular dysplasia/cardiomyopathy (n=312). Inducibility at electrophysiology study vs. No inducibility at electrophysiology study was evaluated on Any appropriate ICD therapy (HR 2.28, 95% CI 1.10-4.70, p=0.025). Inducibility at electrophysiology study independently predicted appropriate ICD therapy in patients with ARVD/C (HR 2.28; 95% CI 1.10-4.70; P=0.025).

synapsesocial.com/papers/6a499f8abaf9dfe185df0399https://doi.org/10.1161/jaha.117.006242
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prophylactic Implantable Defibrillator in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia and No Prior Ventricular Fibrillation or Sustained Ventricular Tachycardia2010 · 309 citations
  2. 2Predictors of Appropriate ICD Therapy in Patients with Arrhythmogenic Right Ventricular Cardiomyopathy: Long Term Experience of a Tertiary Care Center2012 · 38 citations
  3. 3Implantable Cardioverter/Defibrillator Therapy in Arrhythmogenic Right Ventricular Cardiomyopathy2004 · 293 citations
  4. 4Risk Stratification in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy–Associated Desmosomal Mutation Carriers2013 · 102 citations
  5. 5Right ventricular dysplasia: a report of 24 adult cases.1982 · 1,613 citations